This site uses cookies to measure how you use the website so it can be updated and improved based on your needs and also uses cookies to help remember the notifications you’ve seen, like this one, so that we don’t show them to you again. If you could also tell us a little bit about yourself, this information will help us understand how we can support you better and make this site even easier for you to use and navigate.

A randomized, double-blind, placebo-controlled trial of pridopidine in Huntington’s disease


Kieburtz, Karl, McGarry, A, McDermott, M, Huntington Study Group HART Investigators,


Movement Disorders: Official Journal Of The Movement Disorder Society, Volume: 28, No.: 10, Pages.: 1407-1415

Year of Publication



We examined the effects of 3 dosages of pridopidine, a dopamine-stabilizing compound, on motor function and other features of Huntington’s disease, with additional evaluation of its safety and tolerability. This was a randomized, double-blind, placebo-controlled trial in outpatient neurology clinics at 27 sites in the United States and Canada. Two hundred twenty-seven subjects enrolled from October 24, 2009, to May 10, 2010. The intervention was pridopidine, either 20 (n=56), 45 (n=55), or 90 (n=58) mg daily for 12 weeks or matching placebo (n=58). The primary outcome measure was the change from baseline to week 12 in the Modified Motor Score, a subset of the Unified Huntington’s Disease Rating Scale Total Motor Score. Measures of safety and tolerability included adverse events and trial completion on the assigned dosage. After 12 weeks, the treatment effect (relative to placebo, where negative values indicate improvement) of pridopidine 90 mg/day on the Modified Motor Score was -1.2 points (95% confidence interval [CI], -2.5 to 0.1 points; P = .08). The effect on the Total Motor Score was -2.8 points (95% CI, -5.4 to -0.1 points; nominal P = .04). No significant effects were seen in secondary outcome measures with any of the active dosages. Pridopidine was generally well tolerated. Although the primary analysis did not demonstrate a statistically significant treatment effect, the overall results suggest that pridopidine may improve motor function in Huntington’s disease. The 90 mg/day dosage appears worthy of further study. Pridopidine was well tolerated.; © 2013 International Parkinson and Movement Disorder Society.

Bibtex Citation

@article{2013, doi = {10.1002/mds.25362}, url = {}, year = 2013, month = {feb}, publisher = {Wiley-Blackwell}, volume = {28}, number = {10}, pages = {1407--1415}, title = {A randomized, double-blind, placebo-controlled trial of pridopidine in Huntington{textquotesingle}s disease}, journal = {Movement Disorders} }


adult, adverse effects, behavior, clinical trial, cognition, data interpretation statistical, dopamine agents, doseresponse relationship drug, doubleblind method, drug therapy, female, function, humans, huntington disease, huntingtons disease, male, motor, movement, physiology, physiopathology, piperidines, pridopidine, therapeutic use, trail making test, treatment outcome

Countries of Study

Canada, USA

Types of Dementia


Types of Study

Randomised Controlled Trial

Type of Outcomes



Hospital Outpatient Care

Type of Interventions

Pharmaceutical Interventions

Pharmaceutical Interventions